P. Panagiotou

1.0k total citations
15 papers, 724 citations indexed

About

P. Panagiotou is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, P. Panagiotou has authored 15 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in P. Panagiotou's work include Cutaneous Melanoma Detection and Management (7 papers), Immunotherapy and Immune Responses (6 papers) and melanin and skin pigmentation (4 papers). P. Panagiotou is often cited by papers focused on Cutaneous Melanoma Detection and Management (7 papers), Immunotherapy and Immune Responses (6 papers) and melanin and skin pigmentation (4 papers). P. Panagiotou collaborates with scholars based in Greece, United States and United Kingdom. P. Panagiotou's co-authors include Dimosthenis Tsoutsos, Helen Gogas, Aristidis Polyzos, J. Ioannovich, Dimitrios Bafaloukos, George Fountzilas, Dimitrios Pectasides, Konstantina Frangia, Urania Dafni and Christos Markopoulos and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

P. Panagiotou

15 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Panagiotou Greece 10 498 403 240 53 51 15 724
Marina Gualco Italy 14 335 0.7× 354 0.9× 221 0.9× 65 1.2× 51 1.0× 26 697
Christine Hanlon United States 5 409 0.8× 403 1.0× 347 1.4× 60 1.1× 26 0.5× 5 758
Dennis Knapp United States 9 269 0.5× 284 0.7× 398 1.7× 71 1.3× 22 0.4× 11 694
C. Bradley United Kingdom 3 328 0.7× 187 0.5× 225 0.9× 77 1.5× 111 2.2× 6 565
Hua Zhong China 10 302 0.6× 362 0.9× 202 0.8× 54 1.0× 24 0.5× 17 587
A Nizze United States 6 231 0.5× 264 0.7× 165 0.7× 37 0.7× 127 2.5× 7 494
Sijie Lu United States 14 688 1.4× 904 2.2× 254 1.1× 51 1.0× 13 0.3× 25 1.3k
Daniela Achkova United Kingdom 9 253 0.5× 368 0.9× 303 1.3× 60 1.1× 19 0.4× 13 666
A. Y. Bedikian United States 10 390 0.8× 131 0.3× 234 1.0× 29 0.5× 19 0.4× 24 524
Jeffrey S. Painter United States 16 297 0.6× 635 1.6× 474 2.0× 25 0.5× 19 0.4× 28 1.3k

Countries citing papers authored by P. Panagiotou

Since Specialization
Citations

This map shows the geographic impact of P. Panagiotou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Panagiotou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Panagiotou more than expected).

Fields of papers citing papers by P. Panagiotou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Panagiotou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Panagiotou. The network helps show where P. Panagiotou may publish in the future.

Co-authorship network of co-authors of P. Panagiotou

This figure shows the co-authorship network connecting the top 25 collaborators of P. Panagiotou. A scholar is included among the top collaborators of P. Panagiotou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Panagiotou. P. Panagiotou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Njauw, Ching-Ni Jenny, Katerina Kypreou, Vasiliki Chasapi, et al.. (2018). CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters. Acta Dermato Venereologica. 98(9). 862–866. 5 indexed citations
2.
Pančoška, Petr, John M. Kirkwood, Maria Spyropoulou‐Vlachou, et al.. (2014). A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon. PLoS ONE. 9(1). e86375–e86375. 2 indexed citations
3.
Gogas, Helen, Urania Dafni, Henry Koon, et al.. (2010). Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Journal of Translational Medicine. 8(1). 108–108. 16 indexed citations
4.
Pectasides, Dimitrios, Urania Dafni, Dimitrios Bafaloukos, et al.. (2009). Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma. Journal of Clinical Oncology. 27(6). 939–944. 72 indexed citations
5.
Dafni, Urania, Dimosthenis Tsoutsos, P. Panagiotou, et al.. (2008). Prognostic significance of autoimmunity during adjuvant treatment of melanoma with interferon: Updated follow-up. Journal of Clinical Oncology. 26(15_suppl). 9024–9024. 1 indexed citations
6.
Gogas, Helen, J. Ioannovich, Urania Dafni, et al.. (2006). Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. New England Journal of Medicine. 354(7). 709–718. 428 indexed citations
7.
Gogas, Helen, Aristidis Polyzos, Konstantina Frangia, et al.. (2006). Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Annals of Oncology. 17(12). 1835–1841. 19 indexed citations
8.
Stefanaki, Irene, Alexander Stratigos, Vasiliki Nikolaou, et al.. (2006). p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. British Journal of Dermatology. 156(2). 357–362. 20 indexed citations
9.
Bafaloukos, Dimitrios, Dimosthenis Tsoutsos, Haralabos P. Kalofonos, et al.. (2005). Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Annals of Oncology. 16(6). 950–957. 48 indexed citations
10.
Gogas, Helen, Dimitrios Bafaloukos, Gerasimos Aravantinos, et al.. (2004). Vinorelbine in Combination with Interleukin-2 as Second-Line Treatment in Patients with Metastatic Melanoma. A Phase II Study of the Hellenic Cooperative Oncology Group. Cancer Investigation. 22(6). 832–839. 8 indexed citations
11.
Tsoutsos, Dimosthenis, Helena Linardou, Christos Christodoulou, et al.. (2004). The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Research. 14(4). 289–294. 28 indexed citations
12.
Gogas, Helen, Dimitrios Bafaloukos, J. Ioannovich, et al.. (2004). Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.. PubMed. 24(3b). 1947–52. 19 indexed citations
13.
Gogas, Helen, J. Ioannovich, Konstantina Frangia, et al.. (2004). The prevalence of autoantibodies in patients with high risk melanoma receiving adjuvant interferon. Melanoma Research. 14(4). A17–A17. 2 indexed citations
14.
Keramidas, Evangelos, et al.. (2003). Reverse dorsal digital and intercommissural flaps used for digital reconstruction. British Journal of Plastic Surgery. 57(1). 61–65. 19 indexed citations
15.
Gogas, Helen, Georgia Kefala, Dimitrios Bafaloukos, et al.. (2002). Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon. British Journal of Cancer. 87(2). 181–186. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Gualco Breakdown of academic impact, for papers by Christine Hanlon Breakdown of academic impact, for papers by Dennis Knapp Breakdown of academic impact, for papers by C. Bradley Breakdown of academic impact, for papers by Hua Zhong Breakdown of academic impact, for papers by A Nizze Breakdown of academic impact, for papers by Sijie Lu Breakdown of academic impact, for papers by Daniela Achkova Breakdown of academic impact, for papers by A. Y. Bedikian Breakdown of academic impact, for papers by Jeffrey S. Painter
Rankless by CCL
2026